TOURMALINE BIO INC (TRML)
US89157D1054 - Common Stock
TRML Stock Earnings: Tourmaline Bio Beats EPS for Q1 2024
TRML stock results show that Tourmaline Bio beat analyst estimates for earnings per share the first quarter of 2024.
Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
Tourmaline Bio announces financial results and business highlights for the first quarter ended March 31, 2024 ...
Tourmaline Bio is Now Oversold (TRML)
Bag Shares of TRML 8.2% Cheaper Than the CEO Did
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
Investors saw Chugai's experimental drug as a potential rival to Argenx's approved medicine, Vyvgart.
TRML Stock Earnings: Tourmaline Bio Reported Results for Q4 2023
Tourmaline Bio just reported results for the fourth quarter of 2023.
TRML Stock Earnings: Tourmaline Bio Reported Results for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Tourmaline Bio (NASDAQ:TRML) just reported results for the fourth quarter of 20...
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
– Initiated pivotal spiriTED Phase 2b trial in Thyroid Eye Disease (TED) in 2023 and expanded TED clinical development plan, including accelerating the...
Tourmaline Bio to Present at Upcoming Investor Conferences
NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing...
Tourmaline Bio director discloses purchase of stake worth $3.25M (NASDAQ:TRML)
This article discusses insider trading at Tourmaline Bio (TRML), with its director Mark McDade acquiring 100,000 company shares for $3.25 million.
Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
NEW YORK, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing...
Tourmaline Bio to raise ~$150M through public offering of shares (NASDAQ:TRML)
Biotechnology company, Tourmaline Bio, announces pricing of public offering, selling 4.6M shares at $32.50/share to raise ~$150M.
Tourmaline Bio Announces Pricing of Public Offering of Common Stock
Tourmaline Bio Announces Pricing of Public Offering of Common Stock
NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing...
Tourmaline Bio looks to raise cash through a public offering (NASDAQ:TRML)
Tourmaline Bio announces proposed public offering of common stock. Underwriters may purchase additional shares.
Tourmaline Bio Announces Proposed Public Offering of Common Stock
Tourmaline Bio Announces Proposed Public Offering of Common Stock
NEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing...
Tourmaline Bio announces addition to NASDAQ Biotechnology Index (NASDAQ:TRML)
Tourmaline Bio (TRML) has been added to the NASDAQ Biotechnology Index, effective Dec.
Tourmaline Bio added to the NASDAQ Biotechnology Index
Tourmaline Bio added to the NASDAQ Biotechnology Index
NEW YORK, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing...
Tourmaline Bio appoints Clay Siegall as its chair (NASDAQ:TRML)
Tourmaline Bio has appointed Clay Siegall, current president and CEO of Immunone, as its chairman, previously serving as CEO and president of Seagen.
Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board
Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board
NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (NASDAQ: TRML), a late-stage clinical biotechnology company developing...
Tourmaline Bio to Present at Upcoming Investor Conferences
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative...